Answer
Rozanolixizumab interferes with FcRn-mediated IgG recycling and is expected to decrease serum concentrations of intravenous immunoglobulin and IgG-based monoclonal antibodies administered concomitantly or within two weeks after rozanolixizumab.
Sources for this answer
- Rystiggo 140 mg/ml solution for injectionUCB Pharma Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated
Sources checked